BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN - News), announced today that MedImmune, Inc., has exercised its option to obtain an exclusive license to a second antigen target under the parties’ existing antibody-drug conjugate (ADC) collaboration, triggering a $1.5 million payment to Seattle Genetics.
